



We are resolutely moving forward – side by side with our patients. As a “PioNear”, we develop medical innovations and promote people’s well-being through better care. Get well. Live well. This is what Asklepios stands for.

The Management Board: Hafid Rifi, CFO / Marco Walker, COO / Kai Hankeln, CEO / Dr med. Sara Sheikhzadeh, CMO / Joachim Gemmel, COO


More information in the online reports:

[Annual Report](#) [CR Report](#)

Group key figures

	2022	2021
Number of patients	3,570,976	3,542,346
Number of beds	30,749	31,197
Average number of FTEs	49,103	49,967
Revenue	EUR million 5,290	5,118
Consolidated net profit	EUR million 132	106
Return on sales in %	2.5	2.1
Capital expenditure	EUR million 314	333
of which subsidies	96	90
of which own funds	218	242
Total assets	EUR million 6,871	6,572
Equity	EUR million 2,043	1,747
Equity ratio in %	29.7	26.6
Net debt ratio	3.5x	3.6x

ESG organisation



Company profile

- **Leading healthcare group under family ownership**
- **Around 170 healthcare facilities in 14 German federal states**
- **Nationwide German network for holistic healthcare provision:**
 - University hospitals, maximum, basic, primary and specialised care services
 - Specialist hospitals with established specialties
- **Prevention and aftercare:**
 - Rehabilitation clinics
 - Medical centres
- **Evolution of the hospital network into a healthcare group and “digital healthcare companion”**
- **Ever since its foundation, the focus has been on the values of medical quality, innovation and social responsibility**

Investment highlights

- **Attractive acute market**
 - Long-term, increasing demand for healthcare services, independent of economic trends
- **Predictability**
 - Regulated environment with high barriers to market entry
- **Digital HealthyNear**
 - Asklepios is helping shape the digitalisation of healthcare as a pioneer
 - Integration and digitalisation of treatment methods and processes as an opportunity for growth
- **Profitability**
 - Attractive synergy potential due to factors including centralisation and operational excellence
 - Strategic expansion of the value chain, e.g. with solutions in the field of e-health
- **Conservative financing approach**
 - Long-term financing structure with a balanced maturity profile
 - Freely available lines ensure a high degree of flexibility

Main financing instruments

in EUR million	Dates issued	Volume (outstanding)	Coupon	Term
Schuldschein loan agreement	2013 to 2022	1,916	Fixed/FRN	5 to 20 years

in EUR million	Date issued	Programme amount	Coupon	Term
Euro commercial paper programme	Ongoing	500	Discounted	Up to 364 days

in EUR million	Date concluded	Volume	Term
Syndicated revolving credit line	Aug. 2021	550	Until Aug. 2027

Asklepios Kliniken GmbH & Co. KGaA, Hamburg



* Accounted for using the equity method